Robert J. Gould
Chief Executive Officer, Epizyme, Inc.
Companies
- Turnstone Biologics Corp.Board member Jul 20, 2023 to now1
- Fulcrum Therapeutics (United States)Board member Jul 17, 2019 to now2
- Fulcrum Therapeutics (United States)Chief executive officer Jan 27, 2020 to Jun 29, 20233
- Fulcrum Therapeutics (United States)President Jan 27, 2020 to Jun 29, 20233
- Fulcrum Therapeutics (United States)Officer Jul 17, 2019 to Mar 17, 20212
- Epizyme, Inc.Board member May 30, 2013 to Dec 31, 20154
- Epizyme, Inc.Chief executive officer May 30, 2013 to Sep 10, 20154
- Epizyme, Inc.President May 30, 2013 to Sep 10, 20154
Holdings
Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.
Shares held
- Fulcrum Therapeutics (United States) FULC454,864 shares5$1.7M at $3.67Feb 2, 2026
As of each latest filing. The line shows shares held over time.
Recent filings
- Feb 2, 2026Sold 15,000 shares at $10.72 of Fulcrum Therapeutics (United States)5
- Jan 2, 2026Sold 15,000 shares at $10.87 of Fulcrum Therapeutics (United States)6
- Jan 2, 2026Sold 15,000 shares at $11.87 of Fulcrum Therapeutics (United States)7
- Nov 19, 2025Sold 15,000 shares at $11.03 of Fulcrum Therapeutics (United States)8
- Jan 13, 2023Sold 6,766 shares at $15.00 of Fulcrum Therapeutics (United States)9
- Jun 7, 2022Sold 71,435 shares at $8.09 of Fulcrum Therapeutics (United States)10
- Jun 7, 2022Exercised options 71,435 shares at $7.84 of Fulcrum Therapeutics (United States)10
- Jun 6, 2022Sold 24,382 shares at $8.10 of Fulcrum Therapeutics (United States)11
- Jun 6, 2022Exercised options 24,382 shares at $7.84 of Fulcrum Therapeutics (United States)11
- Jun 3, 2022Sold 25,551 shares at $7.95 of Fulcrum Therapeutics (United States)11
- Jun 3, 2022Exercised options 25,551 shares at $7.84 of Fulcrum Therapeutics (United States)11
- Jun 2, 2022Sold 16,689 shares at $7.92 of Fulcrum Therapeutics (United States)11
- Jun 2, 2022Exercised options 16,689 shares at $7.84 of Fulcrum Therapeutics (United States)11
- Apr 7, 2022Sold 5,631 shares at $24.02 of Fulcrum Therapeutics (United States)12
- Apr 7, 2022Exercised options 5,631 shares at $7.84 of Fulcrum Therapeutics (United States)12
- Apr 5, 2022Sold 52,552 shares at $24.26 of Fulcrum Therapeutics (United States)13
- Apr 5, 2022Exercised options 52,552 shares at $7.84 of Fulcrum Therapeutics (United States)13
- Apr 4, 2022Sold 7,235 shares at $24.02 of Fulcrum Therapeutics (United States)13
- Apr 4, 2022Exercised options 7,235 shares at $7.84 of Fulcrum Therapeutics (United States)13
- Apr 1, 2022Sold 34,464 shares at $24.03 of Fulcrum Therapeutics (United States)13
- Apr 1, 2022Exercised options 34,464 shares at $7.84 of Fulcrum Therapeutics (United States)13
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4SEC EDGAREpizyme, Inc., Board member
- 5
- 6SEC EDGARForm 4 filed Feb 4, 2026
- 7SEC EDGARForm 4 filed Jan 6, 2026
- 8SEC EDGARForm 4 filed Nov 21, 2025
- 9SEC EDGARForm 4 filed Jan 13, 2023
- 10SEC EDGARForm 4 filed Jun 8, 2022
- 11SEC EDGARForm 4 filed Jun 6, 2022
- 12SEC EDGARForm 4 filed Apr 11, 2022
- 13SEC EDGARForm 4 filed Apr 5, 2022